ZIVO Bioscience Statistics
Total Valuation
ZIVO Bioscience has a market cap or net worth of 70.37 million. The enterprise value is 70.83 million.
| Market Cap | 70.37M |
| Enterprise Value | 70.83M |
Important Dates
The last earnings date was Monday, May 12, 2025.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ZIVO Bioscience has 3.76 million shares outstanding. The number of shares has increased by 72.21% in one year.
| Current Share Class | 3.76M |
| Shares Outstanding | 3.76M |
| Shares Change (YoY) | +72.21% |
| Shares Change (QoQ) | +5.81% |
| Owned by Insiders (%) | 38.76% |
| Owned by Institutions (%) | n/a |
| Float | 1.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 579.20 |
| PB Ratio | -43.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.34 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.39
| Current Ratio | 0.39 |
| Quick Ratio | 0.20 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -718.09 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -948.38% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 1,271.68% |
| Revenue Per Employee | 17,357 |
| Profits Per Employee | -2.33M |
| Employee Count | 7 |
| Asset Turnover | 0.11 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +125.56% in the last 52 weeks. The beta is 0.05, so ZIVO Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | +125.56% |
| 50-Day Moving Average | 16.69 |
| 200-Day Moving Average | 17.62 |
| Relative Strength Index (RSI) | 58.21 |
| Average Volume (20 Days) | 551 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ZIVO Bioscience had revenue of 121,500 and -16.32 million in losses. Loss per share was -4.77.
| Revenue | 121,500 |
| Gross Profit | 36,450 |
| Operating Income | -16.29M |
| Pretax Income | -16.32M |
| Net Income | -16.32M |
| EBITDA | n/a |
| EBIT | -16.29M |
| Loss Per Share | -4.77 |
Balance Sheet
The company has 517,189 in cash and 974,593 in debt, giving a net cash position of -457,404 or -0.12 per share.
| Cash & Cash Equivalents | 517,189 |
| Total Debt | 974,593 |
| Net Cash | -457,404 |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | -1.62M |
| Book Value Per Share | -0.43 |
| Working Capital | -1.59M |
Cash Flow
| Operating Cash Flow | -4.04M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 30.00% |
| Operating Margin | -13,411.40% |
| Pretax Margin | -13,430.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZIVO Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -72.21% |
| Shareholder Yield | n/a |
| Earnings Yield | -23.19% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 27, 2023. It was a reverse split with a ratio of 0.1666667.
| Last Split Date | Oct 27, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1666667 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |